Transforming the arc of care
Intensive Care Units (ICUs) are Expensive
ICU cost burden totals
$254B
(1% US GDP)
High-cost patients comprise
10%
of total patients
High-cost patients consume
50%
of total resources
Inflammation is the key driver of complications and excess costs
Aurenar is on path to achieve tremendous health and economic impact by addressing inflammation - the underlying cause of life-threatening and costly complications in the ICU.
Our Approach
WEARABLE
NEUROMODULATION
Our ear-worn device boosts the body’s natural control of inflammation by activating a nerve located in the ear with imperceptible and non-invasive stimulation.
Meet Our Team
-
Eric Leuthardt, MD
Chief Executive Officer | Founder
-
Jenna Gorlewicz, PhD
Chief Technology Officer | Founder
-
Anna Huguenard, MD
Chief Medical Officer | Founder
-
Jeff Dunn, JD
Advisor | Founder
-
Jesse Wheeler, PhD
Chief Operations Officer
-
Jeff Caputo
Chief Business Officer
-
Ryan Kight
Chief Financial Officer
-
Deb Barta
Chief Strategy Officer
Meet Our Scientific Advisory Board
-
Greg Zipfel, MD
Washington University
-
Salal Kayrouz, MD
Washington University
-
Sander Connolly, MD
Columbia University
-
Claude Hemphill, MD
University of California, San Francisco
-
Denis Rivet, MD
Virginia Commonwealth University
-
Craig Coopersmith, MD
Emory University
-
Huimahn Alex Choi, MD
McGovern Medical School, UTHealth
Our approach has been successfully demonstrated in multiple randomized controlled clinical pilot studies, showing:
improved patient outcomes,
reduced hospital length of stay, and
lower cost of care.
We are excited to share our published results soon - stay tuned!
Clinical Trials
Awards
-
American Academy of Neurological Surgeons Award
-
American Association of Neurological Surgeons Award
-
Society of NeuroInterventional Surgery Award
-
Neurocricical Care Society Award